Drug Trial Radar · NCT03151551
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
Last checked: Nov 20, 2026Latest source record: Nov 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
566
Actual
Start
Aug 24, 2017
Primary completion
Nov 15, 2018
Study completion Sep 4, 2019
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
Conditions
- Psoriatic Arthritis
Interventions
IxekizumabDrug
Administered SC
AdalimumabDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)Time frame: Week 24
Locations
131 sites in 22 countries. Site status is shown where the registry gives one.
Organizacion Medica de Investigacion - OMI
Ciudad Autonoma de Buenos Aire, Argentina
Instituto Centenario
Ciudad Autonoma de Buenos Aire, Argentina
Hospital Ramos Mejia
Ciudad Autonoma de Buenos Aire, Argentina
Centro de Medicina Familiar Mindout Research
Ciudad Autonoma de Buenos Aire, Argentina
CENUDIAB
Ciudad Autonoma de Buenos Aire, Argentina
Consultora Integral de Salud S.R.L.
Córdoba, Argentina
Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
San Juan, Argentina
Atencion Integral en Reumatología
Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
Clinica Adventista de Belgrano
Ciudad de Buenos Aires, Buenos Aires, Argentina
CER Instituto Medico
Quilmes, Buenos Aires, Argentina
Instituto de Asist Reumatologica Integral
San Fernando, Buenos Aires, Argentina
Centro Medico Privado de Reumatologia
San Miguel de Tucumán, Tucumán Province, Argentina
Combined Rheumatology Practice (CRP)
Kogarah, New South Wales, Australia
Rheumatology, The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Southern Clinical Research Pty Ltd
Hobart, Tasmania, Australia
Emeritus Research
Camberwell, Victoria, Australia
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia
Zentrum für klinische Studien Dr. Ursula Hanusch GmbH
Vienna, Austria
AKH
Vienna, Austria
Rheuma-Zentrum Wien Oberlaa
Vienna, Austria
Reumaclinic
Genk, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Saint Joseph Hospital
Gilly, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium
Hopital Ambroise Pare
Mons, Belgium
Group de recherche en maladies osseuses
Québec, Canada
The Waterside Clinic
Barrie, Ontario, Canada
SKiN Center for Dermatology
Peterborough, Ontario, Canada
Centre de Recherche Musculo-Squelettique
Trois-Rivières, Quebec, Canada
Polmed Research Inc.
Saskatoon, Saskatchewan, Canada
Aalborg Universitetshospital - Psykiatrien
Aalborg, Denmark
Frederiksberg Hospital
Frederiksberg, Capital Region, Denmark
Helsinki University Hospital, HYKS
Helsinki, Finland
Kiljava Medical Research
Hyvinkää, Finland
Terveystalo Kouvola
Kouvola, Finland
Turun Yliopistollinen Keskussairaala
Turku, Finland
Hôpital Trousseau, CHRU de Tours
Chambray-lès-Tours, France
Centre Hospitalier de Vendee Les Oudairies
La Roche-sur-Yon, France
Hopital Edouard Herriot
Lyon, France
Centre hospitalier universitaire Lapeyronie
Montpellier, France
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.